Ethosuximide

CHEMBL696 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
141.2 g/mol
LogP
0.4
Phase
4

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

分子量

141.1700 g/mol

LogP

0.40

TPSA

46.20 Ų

リピンスキーの五則

適合

治療領域

作用機序

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC1(C)CC(=O)NC1=O

InChI

InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

Molecular Formula

C7H11NO2

HBD / HBA

1 / 2

回転可能結合数

1

重原子数

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ethosuximide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL696. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3291. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.